<DOC>
	<DOCNO>NCT00058071</DOCNO>
	<brief_summary>RATIONALE : Amifostine may effective relieve numbness , tingle , symptoms peripheral neuropathy . It yet know whether amifostine effective treat peripheral neuropathy patient receive chemotherapy cancer . PURPOSE : This randomized phase III trial study amifostine see well work compare observation relieve numbness , tingle , symptoms peripheral neuropathy patient receive platinum-based chemotherapy ( cisplatin carboplatin ) cancer .</brief_summary>
	<brief_title>Amifostine Treating Peripheral Neuropathy Patients Who Have Received Chemotherapy Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine , preliminarily , whether amifostine superior treatment , term improve symptom and/or objective finding platinum-induced peripheral neuropathy , patient cancer . - Determine toxicity drug patient . OUTLINE : This randomize , multicenter study . Patients randomize 1 2 treatment arm . - Arm I : Patients receive amifostine IV subcutaneously 3 minute day 1 , 3 , 5 . Treatment continue 12 week absence unacceptable toxicity . Patients observe 12 week . - Arm II : Patients observe 24 week . After 24 week patient may cross treatment arm I . Quality life assess baseline 6 , 12 , 18 , 24 week study entry . Patients follow 6 12 week study treatment , every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : A total 50-100 patient ( 25-50 per treatment arm ) accrue study .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Trophoblastic Neoplasms</mesh_term>
	<mesh_term>Gestational Trophoblastic Disease</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Prior therapy platinumbased chemotherapy regimen malignancy Treatment agent , include paclitaxel , allow Grade 2 great peripheral neuropathy ( numbness , tingle , pain distal extremity ) attribute prior platinumbased chemotherapy Must persist stable 336 month completion chemotherapy Duration neuropathy 3 year No possible cause neuropathy ( e.g. , alcoholism , diabetes , peripheral vascular disease ) PATIENT CHARACTERISTICS : Age 18 Performance status GOG 03 Life expectancy At least 6 month Hematopoietic Not specify Hepatic Bilirubin great 2.0 mg/dL Renal Creatinine great 2.0 mg/dL Calcium least low limit normal Cardiovascular No hypotension No history cerebrovascular accident Other No significant comorbid medical condition would preclude study participation PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics No concurrent chemotherapy No chemotherapy ( include paclitaxel , cisplatin , carboplatin ) least 4 month study entry Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify Other At least 24 hour since prior antihypertensive medication No prior amifostine Prior treatment GOG treatment protocol allow No concurrent monoamine oxidase inhibitors No concurrent neurotoxic agent least 6 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2007</verification_date>
	<keyword>peripheral neuropathy</keyword>
	<keyword>neurotoxicity</keyword>
	<keyword>hydatidiform mole</keyword>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
</DOC>